An exploratory qualitative assessment of patient and clinician perspectives on patient-reported outcome measures and disease-modifying therapies in adults with spinal muscular atrophy
DOI:
https://doi.org/10.2340/jrm.v57.41254Keywords:
adult spinal muscular atrophy, neuromuscular disease, patient-centred care, patient-reported outcome measure, Qualitative Research, Activities of Daily Living, reliability and validityAbstract
Objective: To understand patient, caregiver, and clinician perspectives on patient-reported outcome measures, critical functional domains, and disease-modifying therapies in adult spinal muscular atrophy.
Design: An exploratory qualitative single-site study.
Patients: Ten adults with spinal muscular atrophy and two clinicians participated in semi-structured interviews.
Methods: Semi-structured interviews were conducted virtually or in person with participants after they completed outcome measures at a routine clinic visit. Two researchers analysed transcripts concurrently using a thematic approach to determine themes.
Results: Ten themes were identified among partici-pants. Patient-reported outcome measure preference varied between functional groups and was under-responsive, although it captured meaningful data. Motor stability was most frequently expected with disease-modifying therapy, but participants also reported improved fatigue and respiratory status.
Conclusion: After considering patient goals, functional status, and preferences, patient-reported outcome measures represent a valuable adjunct to standard clinical and research tools. Optimal selection of patient-reported outcome measures requires careful consideration of multiple patient factors. Collaborative development of modified patient-reported outcome measures may yield a responsive, meaningful, and acceptable tool that can be used across a broad functional spectrum.
Downloads
References
Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analy-sis of >72,400 specimens. Eur J Hum Genet 2012; 20: 27–32.
https://doi.org/10.1038/ejhg.2011.134 DOI: https://doi.org/10.1038/ejhg.2011.134
Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: progress and challeng-es. Neurotherapeutics 2015; 12: 290–302.
https://doi.org/10.1007/s13311-014-0314-x DOI: https://doi.org/10.1007/s13311-014-0314-x
Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Preva-lence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review. Orphanet J Rare Dis 2017; 12: 124.
https://doi.org/10.1186/s13023-017-0671-8 DOI: https://doi.org/10.1186/s13023-017-0671-8
Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, Gillingwater TH, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol 2017; 81: 355–368.
https://doi.org/10.1002/ana.24864 DOI: https://doi.org/10.1002/ana.24864
Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atro-phy - new phenotypes, new challenges, new implications for care. J Neuromuscul Dis 2020; 7: 1–13.
https://doi.org/10.3233/JND-190424 DOI: https://doi.org/10.3233/JND-190424
Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N. Twenty-five years of spinal muscular at-rophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genomics Hum Genet 2020; 21: 231–261.
https://doi.org/10.1146/annurev-genom-102319-103602 DOI: https://doi.org/10.1146/annurev-genom-102319-103602
Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 2018; 378: 625–635.
https://doi.org/10.1056/NEJMoa1710504 DOI: https://doi.org/10.1056/NEJMoa1710504
Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med 2017; 377: 1713–1722.
https://doi.org/10.1056/NEJMoa1706198 DOI: https://doi.org/10.1056/NEJMoa1706198
Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. Risdiplam in Type 1 Spinal Muscular Atrophy. N Engl J Med 2021; 384: 915–923.
https://doi.org/10.1056/NEJMoa2009965 DOI: https://doi.org/10.1056/NEJMoa2009965
Günther R, Wurster CD, Brakemeier S, Osmanovic A, Schreiber-Katz O, Petri S, et al. Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a pro-spective European multinational observational study. Lancet Reg Health Eur 2024; 39: 100862.
https://doi.org/10.1016/j.lanepe.2024.100862 DOI: https://doi.org/10.1016/j.lanepe.2024.100862
Hagenacker T, Wurster CD, Günther R, Schreiber-Katz O, Osmanovic A, Petri S, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol 2020; 19: 317–325.
https://doi.org/10.1016/S1474-4422(20)30037-5 DOI: https://doi.org/10.1016/S1474-4422(20)30037-5
Yeo CJJ, Tizzano EF, Darras BT. Challenges and opportunities in spinal muscular atrophy therapeutics. Lancet Neurol 2024; 23: 205–218.
https://doi.org/10.1016/S1474-4422(23)00419-2 DOI: https://doi.org/10.1016/S1474-4422(23)00419-2
Serrão C, Domingues S, de Campos CF, Moreira S, Conceição I, de Carvalho M, et al. Nusinersen in adults with type 3 spinal muscular atrophy: long-term outcomes on motor and respiratory function. Neurol Sci 2024; 45: 2887–2891.
https://doi.org/10.1007/s10072-024-07515-7 DOI: https://doi.org/10.1007/s10072-024-07515-7
Querin G, Lenglet T, Debs R, Stojkovic T, Behin A, Salachas F, et al. Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study. J Neurol 2021; 268: 1792–1802.
https://doi.org/10.1007/s00415-020-10332-5 DOI: https://doi.org/10.1007/s00415-020-10332-5
Duong T, Wolford C, McDermott MP, Macpherson CE, Pasternak A, Glanzman AM, et al. Nusinersen Treatment in Adults With Spinal Muscular Atrophy. Neurol Clin Pract 2021; 11: e317–e327. DOI: https://doi.org/10.1212/CPJ.0000000000001033
Mercuri E, Pera MC, Scoto M, Finkel R, Muntoni F. Spinal muscular atrophy — insights and challenges in the treatment era. Nat Rev Neurol 2020; 16: 706–715.
https://doi.org/10.1038/s41582-020-00413-4 DOI: https://doi.org/10.1038/s41582-020-00413-4
Mercuri E, Sansone V. Nusinersen in adults with spinal muscular atrophy: new challeng-es. Lancet Neurol 2020; 19: 283–284.
https://doi.org/10.1016/S1474-4422(20)30068-5 DOI: https://doi.org/10.1016/S1474-4422(20)30068-5
Slayter J, Hodgkinson V, Lounsberry J, Brais B, Chapman KM, Genge A, et al. A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Con-sensus using a Modified Delphi Method. J Neuromuscul Dis 2021; 8: 579–588.
https://doi.org/10.3233/jnd-200617 DOI: https://doi.org/10.3233/JND-200617
Slayter J, Casey L, O’Connell C. Patient Reported Outcome Measures in Adult Spinal Muscular Atrophy: A Scoping Review and Graphical Visualization of the Evidence. J Neu-romuscul Dis 2023; 10: 239–250.
https://doi.org/10.3233/JND-221595 DOI: https://doi.org/10.3233/JND-221595
Mercuri E, Messina S, Montes J, Muntoni F, Sansone VA, Antonaci L, et al. Patient and par-ent oriented tools to assess health-related quality of life, activity of daily living and care-giver burden in SMA. Neuromuscul Disord 2020; 30: 431–436.
https://doi.org/10.1016/j.nmd.2020.02.019 DOI: https://doi.org/10.1016/j.nmd.2020.02.019
Sansone VA, Walter MC, Attarian S, Delstanche S, Mercuri E, Lochmüller H, et al. Measur-ing Outcomes in Adults with Spinal Muscular Atrophy – Challenges and Future Direc-tions – Meeting Report. J Neuromuscul Dis 2020; 7: 523–524.
https://doi.org/10.3233/JND-200534 DOI: https://doi.org/10.3233/JND-200534
Zizzi CE, Luebbe E, Mongiovi P, Hunter M, Dilek N, Garland C, et al. The Spinal Muscular Atrophy Health Index: A novel outcome for measuring how a patient feels and functions. Muscle Nerve 2021; 63: 837–844.
https://doi.org/10.1002/mus.27223 DOI: https://doi.org/10.1002/mus.27223
Trundell D, Skalicky A, Staunton H, Hareendran A, Le Scouiller S, Barrett L, et al. Develop-ment of the SMA independence scale–upper limb module (SMAIS–ULM): A novel scale for individuals with Type 2 and non-ambulant Type 3 SMA. J Neurol Sci 2022; 432: 120059.
https://doi.org/10.1016/j.jns.2021.120059 DOI: https://doi.org/10.1016/j.jns.2021.120059
de Lemus M, Cattinari MG, Pascual SI, Medina J, García M, Magallón A, et al. Identification of the most relevant aspects of spinal muscular atrophy (SMA) with impact on the quality of life of SMA patients and their caregivers: the PROfuture project, a qualitative study. J Patient-Rep Outcomes 2024; 8: 78.
https://doi.org/10.1186/s41687-024-00758-0 DOI: https://doi.org/10.1186/s41687-024-00758-0
Greenhalgh J, Gooding K, Gibbons E, Dalkin S, Wright J, Valderas J, et al. How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? A realist synthesis. J Patient-Rep Outcomes 2018; 2: 42.
https://doi.org/10.1186/s41687-018-0061-6 DOI: https://doi.org/10.1186/s41687-018-0061-6
Krogsgaard MR, Brodersen J, Christensen KB, Siersma V, Kreiner S, Jensen J, et al. What is a PROM and why do we need it? Scand J Med Sci Sports 2021; 31: 967–971. DOI: https://doi.org/10.1111/sms.13892
Patient-reported outcome measures (PROMs) | CIHI [Internet]. [cited 2024 Nov 28]. Avail-able from: https://www.cihi.ca/en/patient-reported-outcome-measures-proms
Rodriguez-Torres RS, Uher D, Gay EL, Coratti G, Dunaway Young S, Rohwer A, et al. Meas-uring fatigue and fatigability in spinal muscular atrophy (SMA): challenges and opportu-nities. J Clin Med 2023; 12: 3458.
https://doi.org/10.3390/jcm12103458 DOI: https://doi.org/10.3390/jcm12103458
Walter MC, Chiriboga C, Duong T, Goemans N, Mayhew A, Ouillade L, et al. Improving care and empowering adults living with SMA: a call to action in the new treatment era. J Neu-romuscul Dis 2021; 8: 543–551.
https://doi.org/10.3233/JND-200611 DOI: https://doi.org/10.3233/JND-200611
McGraw S, Qian Y, Henne J, Jarecki J, Hobby K, Yeh WS. A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol 2017; 17: 68.
https://doi.org/10.1186/s12883-017-0853-y DOI: https://doi.org/10.1186/s12883-017-0853-y
Wu JW, Pepler L, Maturi B, Afonso ACF, Sarmiento J, Haldenby R. Systematic review of mo-tor function scales and patient-reported outcomes in spinal muscular atrophy. Am J Phys Med Rehabil 2022; 101: 590–608.
https://doi.org/10.1097/PHM.0000000000001869 DOI: https://doi.org/10.1097/PHM.0000000000001869
Messina S, Frongia AL, Antonaci L, Pera MC, Coratti G, Pane M, et al. A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy. Neuromuscul Disord 2019; 29: 940–950.
https://doi.org/10.1016/j.nmd.2019.10.001 DOI: https://doi.org/10.1016/j.nmd.2019.10.001
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006; 3: 77–101.
https://doi.org/10.1191/1478088706qp063oa DOI: https://doi.org/10.1191/1478088706qp063oa
Mongiovi P, Dilek N, Garland C, Hunter M, Kissel JT, Luebbe E, et al. Patient reported im-pact of symptoms in spinal muscular atrophy (PRISM-SMA). Neurology 2018; 91: e1206–e1214.
https://doi.org/10.1212/WNL.0000000000006241 DOI: https://doi.org/10.1212/WNL.0000000000006241
Osmanovic A, Ranxha G, Kumpe M, Müschen L, Binz C, Wiehler F, et al. Treatment expecta-tions and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy. J Neurol 2020; 267: 2398–2407.
https://doi.org/10.1007/s00415-020-09847-8 DOI: https://doi.org/10.1007/s00415-020-09847-8
Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. Saturation in quali-tative research: exploring its conceptualization and operationalization. Qual Quant 2018; 52: 1893–1907.
https://doi.org/10.1007/s11135-017-0574-8 DOI: https://doi.org/10.1007/s11135-017-0574-8
Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: A systematic review of empirical tests. Soc Sci Med 2022; 292: 114523.
https://doi.org/10.1016/j.socscimed.2021.114523 DOI: https://doi.org/10.1016/j.socscimed.2021.114523
Elsheikh B, King W, Arnold W, Kissel J. Reliability of spinal muscular atrophy functional rating scale (SMAFRS) in ambulatory adults with spinal muscular atrophy. Neurology 2018; 90.
https://doi.org/10.1212/WNL.90.15_supplement.P4.452 DOI: https://doi.org/10.1212/WNL.90.15_supplement.P4.452
Steffensen BF, Mayhew A, Aloysius A, Eagle M, Mercuri E, Messina S, et al. T.P.1.07 Egen classification revisited in SMA. Neuromuscul Disord 2008; 18: 740–741.
https://doi.org/10.1016/j.nmd.2008.06.059 DOI: https://doi.org/10.1016/j.nmd.2008.06.059
Dany A, Rapin A, Lavard B, Novella JL, Jolly D, Boyer FC. Evaluating changes in quality of life using QoL-NMD in patients with neuromuscular diseases. Ann Phys Rehabil Med 2016; 59: e60. DOI: https://doi.org/10.1016/j.rehab.2016.07.139
https://doi.org/10.1080/09638288.2016.1191552 DOI: https://doi.org/10.1080/09638288.2016.1191552
Post MWM, van der Zee CH, Hennink J, Schafrat CG, Visser-Meily JMA, van Berlekom SB. Validity of the Utrecht Scale for evaluation of rehabilitation-participation. Disabil and Re-habil 2012; 34: 478–485.
https://doi.org/10.3109/09638288.2011.608148 DOI: https://doi.org/10.3109/09638288.2011.608148
Miles MB, Huberman MA, Saldana J. Qualitative Data Analysis: A Methods Sourcebook. California: SAGE Publications; 2020, 408 p.
Verhaak PFM, Heijmans MJWM, Peters L, Rijken M. Chronic disease and mental disorder. Soc Sci Med 2005; 60: 789–797.
https://doi.org/10.1016/j.socscimed.2004.06.012 DOI: https://doi.org/10.1016/j.socscimed.2004.06.012
McKnight PE, Kashdan TB. The importance of functional impairment to mental health outcomes: A case for reassessing our goals in depression treatment research. Clin Psy-chol Rev 2009; 29: 243–259.
https://doi.org/10.1016/j.cpr.2009.01.005 DOI: https://doi.org/10.1016/j.cpr.2009.01.005
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Jeremy Slayter, Lauren Casey, Shane McCullum, Dorothy Drost, Allison Banks, Colleen O'Connell
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized JRM contents is available freely online. The Foundation for Rehabilitation Medicine owns the copyright for all material published until volume 40 (2008), as from volume 41 (2009) authors retain copyright to their work and as from volume 49 (2017) the journal has been published Open Access, under CC-BY-NC licences (unless otherwise specified). The CC-BY-NC licenses allow third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
From 2024, articles are published under the CC-BY licence. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.
